Novel Preoperative Type IV Collagen to Predict the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Related Cirrhotic Portal Hypertension After Laparoscopic Splenectomy and Azygoportal Disconnection

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics 2023. CA. Cancer J Clin. 2023;73:17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. 慢性乙型肝炎防治指南(2019)年版 [The guidelines of prevention and treatment for chronic hepatitis B (2019 version)]. Zhonghua Gan Zang Bing Za Zhi. 2019;27:938–961. Chinese. doi:10.3760/cma.j.issn.1007-3418.2019.12.007
   PubMedGoogle Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China 2015. CA. Cancer J Clin. 2016;66:115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Papatheodoridis GV, Goulis J, et al. The impact of newer nucleos (t) ide analogues on patients with hepatitis B decompensated cirrhosis. Ann Gastroenterol. 2015;28:109.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang ZG, Long X, et al. Severe complications after splenic artery embolization for portal hypertension due to hepatic cirrhosis. Risk Manag Healthc Policy. 2020;13:135–140. doi:10.2147/RMHP.S234628
   PubMed Web of Science ®Google Scholar
• Singal AG, Zhang E, Narasimman M, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2022;77(1):128–139. doi:10.1016/j.jhep.2022.01.023
   PubMed Web of Science ®Google Scholar
• Bai DS, Chen P, Jin SJ, Qian JJ, Jiang GQ. Vagus nerve-preserving versus conventional laparoscopic splenectomy and azygoportal disconnection. Surg Endosc. 2018;32:2696–2703. doi:10.1007/s00464-017-5965-3
   PubMed Web of Science ®Google Scholar
• Bai DS, Qian JJ, Chen P, et al. Laparoscopic azygoportal disconnection with and without splenectomy for portal hypertension. Int J Surg. 2016;34:116–121. doi:10.1016/j.ijsu.2016.08.519
   PubMed Web of Science ®Google Scholar
• Gao TM, Zhou J, Xiang XX, et al. Splenectomy and azygoportal disconnection decreases the risk of hepatocellular carcinoma for cirrhosis patients with portal hypertension bleeding: a 10-year retrospective follow-up study based on the inverse probability of treatment weighting method. J Gastroenterol. 2023;58:503–512. doi:10.1007/s00535-023-01982-z
   PubMed Web of Science ®Google Scholar
• Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. 2020;371:m3544. doi:10.1136/bmj.m3544
   PubMed Web of Science ®Google Scholar
• Harris R, Harman DJ, Card TR, Aithal GP, Guha IN. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. Lancet Gastroenterol Hepatol. 2017;2(4):288–297. doi:10.1016/S2468-1253(16)30205-9
   PubMed Web of Science ®Google Scholar
• Mei L, Ma Y, Zhao LL, et al. Correlation between serum liver fibrosis markers and early gastroesophageal varices among patients with compensated liver cirrhosis: a cross-sectional analysis. BMC Gastroenterol. 2022;22(1):515. doi:10.1186/s12876-022-02546-w
   PubMed Web of Science ®Google Scholar
• El-Mezayen HA, Habib S, Marzok HF, Saad MH. Diagnostic performance of collagen IV and laminin for the prediction of fibrosis and cirrhosis in chronic hepatitis C patients: a multicenter study. Eur J Gastroenterol Hepatol. 2015;27:378–385. doi:10.1097/MEG.0000000000000298
   PubMed Web of Science ®Google Scholar
• Cholankeril G, Kramer JR, Chu J, et al. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. J Hepatol. 2023;78:493–500. doi:10.1016/j.jhep.2022.10.035
   PubMed Web of Science ®Google Scholar
• Affo S, Yu LX, Schwabe RF. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol. 2017;12:153–186. doi:10.1146/annurev-pathol-052016-100322
   PubMed Web of Science ®Google Scholar
• Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med. 2020;245:96–108. doi:10.1177/1535370219898141
   PubMed Web of Science ®Google Scholar
• Jiang GQ, Bai DS, Chen P, et al. Modified laparoscopic splenectomy and azygoportal disconnection combined with cell salvage is feasible and might reduce the need for blood transfusion. World J Gastroenterol. 2014;20:18420–18426. doi:10.3748/wjg.v20.i48.18420
   PubMed Web of Science ®Google Scholar
• Bantis LE, Tsimikas JV, Chambers GR, Capello M, Hanash S, Feng Z. The length of the receiver operating characteristic curve and the two cutoff Youden index within a robust framework for discovery, evaluation, and cutoff estimation in biomarker studies involving improper receiver operating characteristic curves. Stat Med. 2021;40(7):1767–1789. doi:10.1002/sim.8869
   PubMed Web of Science ®Google Scholar
• Williamson EJ, Forbes A, White IR. Variance reduction in randomised trials by inverse probability weighting using the propensity score. Stat Med. 2014;33:721–737. doi:10.1002/sim.5991
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D. CONSORT statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7(3):e1000251.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–1314. doi:10.1016/S0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Daulagala AC, Kourtidis A. ECM substrates impact RNAi localization at adherens junctions of colon epithelial cells. Cells. 2022;11(23):3740. doi:10.3390/cells11233740
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Daniels SJ, Holm Nielsen S, et al. Collagen biology and non-invasive biomarkers of liver fibrosis. Liver Int. 2020;40(4):736–750. doi:10.1111/liv.14390
   PubMed Web of Science ®Google Scholar
• Nyormoi O, Mills L, Bar-Eli M. An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Differ. 2003;10:558–569. doi:10.1038/sj.cdd.4401209
   PubMed Web of Science ®Google Scholar
• Eissa S, Ali-Labib R, Swellam M, Bassiony M, Tash F, El-Zayat TM. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol. 2007;52:1388–1396. doi:10.1016/j.eururo.2007.04.006
   PubMed Web of Science ®Google Scholar
• Sang QX. Complex role of matrix metalloproteinases in angiogenesis. Cell Res. 1998;8:171–177. doi:10.1038/cr.1998.17
   PubMedGoogle Scholar
• Kowalczyk A, Nisiewicz MK, Bamburowicz-Klimkowska M, et al. Effective voltammetric tool for simultaneous detection of MMP-1, MMP-2, and MMP-9; important non-small cell lung cancer biomarkers. Biosens Bioelectron. 2023;229:115212. doi:10.1016/j.bios.2023.115212
   PubMed Web of Science ®Google Scholar
• Cavdar Z, Canda AE, Terzi C, Sarioglu S, Fuzun M, Oktay G. Role of gelatinases (matrix metalloproteinases 2 and 9), vascular endothelial growth factor and endostatin on clinicopathological behaviour of rectal cancer. Colorectal Dis. 2011;13:154–160. doi:10.1111/j.1463-1318.2009.02105.x
   PubMed Web of Science ®Google Scholar
• Niu A, Qi TG. Diagnostic significance of serum type IV collagen (IVC) combined with aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio in liver fibrosis. Ann Transl Med. 2022;10:1310. doi:10.21037/atm-22-5010
   PubMed Web of Science ®Google Scholar
• Ordoñez R, Carbajo-Pescador S, Prieto-Dominguez N, García-Palomo A, González-Gallego J, Mauriz JL. Inhibition of matrix metalloproteinase-9 and nuclear factor kappa B contribute to melatonin prevention of motility and invasiveness in HepG2 liver cancer cells. J Pineal Res. 2014;56:20–30. doi:10.1111/jpi.12092
   PubMed Web of Science ®Google Scholar
• Seong G, Sinn DH, Kang W, et al. Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase. Eur J Gastroenterol Hepatol;2022. 69–75. doi:10.1097/MEG.0000000000001915
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Nishijima N, Enomoto H, et al. Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir. J Cancer;2017. 152–161. doi:10.7150/jca.16523
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu C, Su TH, et al. Fibrosis-4 index helps identify HBV carriers with the lowest risk of hepatocellular carcinoma. Am J Gastroenterol. 2017;112:1564–1574. doi:10.1038/ajg.2017.254
   PubMed Web of Science ®Google Scholar
• Chen TJ, Dai XW, Dai JJ, et al. AFP promotes HCC progression by suppressing the HuR-mediated Fas/FADD apoptotic pathway. Cell Death Dis. 2020;11:822. doi:10.1038/s41419-020-03030-7
   PubMed Web of Science ®Google Scholar